880 related articles for article (PubMed ID: 29132396)
1. Circulating cell-free DNA and circulating tumor cells, the "liquid biopsies" in ovarian cancer.
Cheng X; Zhang L; Chen Y; Qing C
J Ovarian Res; 2017 Nov; 10(1):75. PubMed ID: 29132396
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
[TBL] [Abstract][Full Text] [Related]
3. Liquid biopsy in ovarian cancer.
Giannopoulou L; Lianidou ES
Adv Clin Chem; 2020; 97():13-71. PubMed ID: 32448432
[TBL] [Abstract][Full Text] [Related]
4. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA.
Giannopoulou L; Kasimir-Bauer S; Lianidou ES
Clin Chem Lab Med; 2018 Jan; 56(2):186-197. PubMed ID: 28753534
[TBL] [Abstract][Full Text] [Related]
5. The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations.
Esposito A; Criscitiello C; Trapani D; Curigliano G
Curr Oncol Rep; 2017 Jan; 19(1):1. PubMed ID: 28110461
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor cells as a "real-time liquid biopsy": Recent advances and the application in ovarian cancer.
Jou HJ; Ling PY; Hsu HT
Taiwan J Obstet Gynecol; 2022 Jan; 61(1):34-39. PubMed ID: 35181043
[TBL] [Abstract][Full Text] [Related]
7. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
[TBL] [Abstract][Full Text] [Related]
8. Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities.
Esposito A; Bardelli A; Criscitiello C; Colombo N; Gelao L; Fumagalli L; Minchella I; Locatelli M; Goldhirsch A; Curigliano G
Cancer Treat Rev; 2014 Jun; 40(5):648-55. PubMed ID: 24184333
[TBL] [Abstract][Full Text] [Related]
9. Potential clinical utility of liquid biopsies in ovarian cancer.
Zhu JW; Charkhchi P; Akbari MR
Mol Cancer; 2022 May; 21(1):114. PubMed ID: 35545786
[TBL] [Abstract][Full Text] [Related]
10. The application of circulating tumor cell and cell-free DNA liquid biopsies in ovarian cancer.
Balla A; Bhak J; Biró O
Mol Cell Probes; 2022 Dec; 66():101871. PubMed ID: 36283501
[TBL] [Abstract][Full Text] [Related]
11. ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.
Chebouti I; Kuhlmann JD; Buderath P; Weber S; Wimberger P; Bokeloh Y; Hauch S; Kimmig R; Kasimir-Bauer S
Oncotarget; 2017 Apr; 8(15):24303-24313. PubMed ID: 28388557
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the liquid biopsy for the detection of BRAFV600E mutation in metastatic melanoma patients.
Salvianti F; Massi D; De Giorgi V; Gori A; Pazzagli M; Pinzani P
Cancer Biomark; 2019; 26(3):271-279. PubMed ID: 31524142
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer.
Nordgård O; Tjensvoll K; Gilje B; Søreide K
Br J Surg; 2018 Jan; 105(2):e110-e120. PubMed ID: 29341153
[TBL] [Abstract][Full Text] [Related]
14. Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes.
Giannopoulou L; Zavridou M; Kasimir-Bauer S; Lianidou ES
Transl Res; 2019 Mar; 205():77-91. PubMed ID: 30391474
[TBL] [Abstract][Full Text] [Related]
15. The potential of liquid biopsies in gastrointestinal cancer.
Wu C; Zhang J; Li H; Xu W; Zhang X
Clin Biochem; 2020 Oct; 84():1-12. PubMed ID: 32540214
[TBL] [Abstract][Full Text] [Related]
16. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
Fici P
Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
[TBL] [Abstract][Full Text] [Related]
17. Liquid Biopsy: Approaches to Dynamic Genotyping in Cancer.
von Bubnoff N
Oncol Res Treat; 2017; 40(7-8):409-416. PubMed ID: 28693026
[TBL] [Abstract][Full Text] [Related]
18. Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer.
Jiang N; Pan J; Fang S; Zhou C; Han Y; Chen J; Meng X; Jin X; Gong Z
Clin Chim Acta; 2019 Aug; 495():331-337. PubMed ID: 31054913
[TBL] [Abstract][Full Text] [Related]
19. Liquid biopsy for ovarian cancer using circulating tumor cells: Recent advances on the path to precision medicine.
Yang J; Cheng S; Zhang N; Jin Y; Wang Y
Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188660. PubMed ID: 34800546
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer.
He J; Tan W; Ma J
Future Oncol; 2017 Apr; 13(9):787-797. PubMed ID: 28073294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
